Ndra a good buy for 2025

**Endra Life Sciences (NDRA) does not appear to be a strong buy for 2025 based on the available financial data.** Here's why:

1. **Financial Performance**: The company's financials show a decline in net income and diluted EPS over the past three years, with a net income CAGR of -5.36% and a diluted EPS CAGR of -46.64%. Additionally, the diluted EPS for the trailing twelve months ended in June 2024 was $-39.50, which is a significant negative figure indicating losses rather than profits.

2. **Stock Price and Market Sentiment**: The stock has experienced a significant downturn, with a 1-year change of -99.35%, reaching a 52-week low of $0.37. The pre-market movements show volatility with gains and losses, but the recent trend has been positive with a 6.2% gain.

3. **Market Position and Product Pipeline**: ENDRA is developing innovative biomedical imaging technology, but the market conditions and the company's financial health raise concerns. The extension granted to regain compliance with Nasdaq's continued listing requirements is a sign of the challenges the company faces.
4. **Insider Activity**: UBS Group AG has acquired additional shares, which could be a positive sign for confidence from a major stakeholder. However, the overall insider transactions do not provide a comprehensive view of the company's prospects.
5. **Industry and Economic Considerations**: The broader biotech industry and economic landscape can impact individual stock performance. ENDRA's strategic updates and positive developments, such as the issuance of new patents, could be potential upside factors.

In conclusion, while there are some positive developments and insider activities that could be indicative of potential growth, the current financial data and market conditions suggest that NDRA may not be a compelling buy for 2025 at this time. Investors should closely monitor the company's progress in overcoming its financial challenges and executing on its product pipeline.